Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GB-2064 by Galecto for Myelofibrosis: Likelihood of Approval
GB-2064 is under clinical development by Galecto and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...
Selvigaltin by Galecto for Metastatic Melanoma: Likelihood of Approval
Selvigaltin is under clinical development by Galecto and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Selvigaltin by Galecto for Decompensated Cirrhosis: Likelihood of Approval
Selvigaltin is under clinical development by Galecto and currently in Phase II for Decompensated Cirrhosis. According to GlobalData, Phase II...
Selvigaltin by Galecto for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Selvigaltin is under clinical development by Galecto and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....